GlobeNewswire Clinical StudiesOriginal article
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
Phase 2positive4D-150Positive
AI Analysis
Summary
4D Molecular Therapeutics announced positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150, an intravitreal gene therapy, in patients with wet AMD. The data were presented at the 44th Annual Scientific Meeting of the American Society of Retina Specialists.
Clinical Trial Data
Phase
2b
Primary Endpoint
Met
Outcome Details
Positive 2-year data from PRISM Phase 2b trial in broad wet AMD population
Importance:7/10
Sentiment:
0.85
gene therapyophthalmologywet AMDintravitrealdata readoutASRS conference
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 18, 2026 7:15 PM